We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Dentsply (XRAY) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
Read MoreHide Full Article
In its upcoming report, Dentsply International (XRAY - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.43 per share, reflecting a decline of 2.3% compared to the same period last year. Revenues are forecasted to be $919.36 million, representing a year-over-year decrease of 9.2%.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Dentsply metrics that are commonly monitored and projected by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Net sales- Connected Technology Solutions' of $296.59 million. The estimate indicates a year-over-year change of -7%.
The combined assessment of analysts suggests that 'Net sales- Wellspect Healthcare' will likely reach $76.04 million. The estimate points to a change of +0.1% from the year-ago quarter.
Analysts forecast 'Net sales- Essential Dental Solutions' to reach $337.26 million. The estimate points to a change of -5.8% from the year-ago quarter.
Based on the collective assessment of analysts, 'Net sales- Orthodontic and Implant Solutions' should arrive at $207.43 million. The estimate indicates a change of -19.9% from the prior-year quarter.
It is projected by analysts that the 'Revenues- Rest of World' will reach $205.38 million. The estimate suggests a change of -16.9% year over year.
According to the collective judgment of analysts, 'Revenues- Europe' should come in at $368.16 million. The estimate indicates a year-over-year change of -7.3%.
Over the past month, Dentsply shares have recorded returns of -2.9% versus the Zacks S&P 500 composite's -1.8% change. Based on its Zacks Rank #4 (Sell), XRAY will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Dentsply (XRAY) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates
In its upcoming report, Dentsply International (XRAY - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.43 per share, reflecting a decline of 2.3% compared to the same period last year. Revenues are forecasted to be $919.36 million, representing a year-over-year decrease of 9.2%.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Dentsply metrics that are commonly monitored and projected by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Net sales- Connected Technology Solutions' of $296.59 million. The estimate indicates a year-over-year change of -7%.
The combined assessment of analysts suggests that 'Net sales- Wellspect Healthcare' will likely reach $76.04 million. The estimate points to a change of +0.1% from the year-ago quarter.
Analysts forecast 'Net sales- Essential Dental Solutions' to reach $337.26 million. The estimate points to a change of -5.8% from the year-ago quarter.
Based on the collective assessment of analysts, 'Net sales- Orthodontic and Implant Solutions' should arrive at $207.43 million. The estimate indicates a change of -19.9% from the prior-year quarter.
It is projected by analysts that the 'Revenues- Rest of World' will reach $205.38 million. The estimate suggests a change of -16.9% year over year.
According to the collective judgment of analysts, 'Revenues- Europe' should come in at $368.16 million. The estimate indicates a year-over-year change of -7.3%.
View all Key Company Metrics for Dentsply here>>>
Over the past month, Dentsply shares have recorded returns of -2.9% versus the Zacks S&P 500 composite's -1.8% change. Based on its Zacks Rank #4 (Sell), XRAY will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>